Hanmi Says Sanofi Made 'Optimal' Efpeglenatide Decision, Still Eyes 2021 Approval

Hanmi Pharm is remaining upbeat after Sanofi’s decision to find another commercialization partner for efpeglenatide, saying it was the best strategy for the long-acting GLP-1 agonist given the strategic change in the big pharma’s diabetes strategy.